Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency

D. K. Klassen, R. L. Stout, P. S. Spilman, A. Whelton

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to evaluate the pharmacokinetics of sulindac, a purported 'renal sparing' nonsteroidal anti-inflammatory drug, and its effects on renal function and prostaglandin excretion in patients with reduced glomerular filtration rate. Twelve female patients (glomerular filtration rate 37 ± 4 mL/min) were treated with sulindac 200 mg bid for 11 days. Urinary PGE2, 6-keto-PGF(1α), and serum thromboxane (TxB2) generation were measured by radioimmunoassay (RIA) following extraction on C-18 columns. Glomerular filtration rate and effective renal plasma flow were measured by 99TC-DPTA and 131I-para-aminohippuric acid clearance. In six patients serum and urine levels of sulindac and its metabolites were measured by high-pressure liquid chromatography (HPLC). Sulindac was rapidly absorbed and converted to sulindac sulfide with peak levels 2 hours after a single dose, but steady state levels were not reached prior to drug discontinuation. Sulindac sulfide AUC (0-5 hours μg min/mL) progressively increased from 382 to 3,030 on day 11. It did not appear in the urine. Baseline urinary PGE2 and 6-keto-PGF(1α) excretion were 23.8 ± 5.6 and 18.9 ± 2.7 ng/hr respectively and were reduced by 68% and 47% by day 4 of therapy. TxB2 generation fell by 34% after one dose and by 67% by day 11. There was a significant increase in serum creatinine from 1.88 ± 0.13 mg/dl before treatment to 2.16 ± 0.15 mg/dL (P <.05) after eleven days. There was a significant (P <.001) decrease in effective renal plasma flow, 184.9 ± 16.3 mL/min before therapy vs 164.1 ± 17.0 mL/min on day 11 of therapy. Glomerular filtration rate (GFR) was significantly reduced following 4 days of therapy (P <.05: day 1 vs day 4) but by day 11 had returned to baseline. We concluded than in this population the active sulindac sulfide metabolite accumulates systemically and can significantly inhibit renal prostaglandin metabolism as well as peripheral TxB2 generation and may effect renal function.

Original languageEnglish (US)
Pages (from-to)1037-1042
Number of pages6
JournalJournal of Clinical Pharmacology
Volume29
Issue number11
StatePublished - 1989

Fingerprint

Sulindac
Prostaglandins
Renal Insufficiency
Glomerular Filtration Rate
Kidney
Effective Renal Plasma Flow
Prostaglandins F
Dinoprostone
Serum
Urine
p-Aminohippuric Acid
Therapeutics
Cohort Effect
Thromboxanes
Pharmaceutical Preparations
Area Under Curve
Radioimmunoassay
Creatinine
Anti-Inflammatory Agents
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Klassen, D. K., Stout, R. L., Spilman, P. S., & Whelton, A. (1989). Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. Journal of Clinical Pharmacology, 29(11), 1037-1042.

Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. / Klassen, D. K.; Stout, R. L.; Spilman, P. S.; Whelton, A.

In: Journal of Clinical Pharmacology, Vol. 29, No. 11, 1989, p. 1037-1042.

Research output: Contribution to journalArticle

Klassen, DK, Stout, RL, Spilman, PS & Whelton, A 1989, 'Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency', Journal of Clinical Pharmacology, vol. 29, no. 11, pp. 1037-1042.
Klassen, D. K. ; Stout, R. L. ; Spilman, P. S. ; Whelton, A. / Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. In: Journal of Clinical Pharmacology. 1989 ; Vol. 29, No. 11. pp. 1037-1042.
@article{540a34055d2e48c2a87b01739e6503e4,
title = "Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency",
abstract = "The purpose of this study was to evaluate the pharmacokinetics of sulindac, a purported 'renal sparing' nonsteroidal anti-inflammatory drug, and its effects on renal function and prostaglandin excretion in patients with reduced glomerular filtration rate. Twelve female patients (glomerular filtration rate 37 ± 4 mL/min) were treated with sulindac 200 mg bid for 11 days. Urinary PGE2, 6-keto-PGF(1α), and serum thromboxane (TxB2) generation were measured by radioimmunoassay (RIA) following extraction on C-18 columns. Glomerular filtration rate and effective renal plasma flow were measured by 99TC-DPTA and 131I-para-aminohippuric acid clearance. In six patients serum and urine levels of sulindac and its metabolites were measured by high-pressure liquid chromatography (HPLC). Sulindac was rapidly absorbed and converted to sulindac sulfide with peak levels 2 hours after a single dose, but steady state levels were not reached prior to drug discontinuation. Sulindac sulfide AUC (0-5 hours μg min/mL) progressively increased from 382 to 3,030 on day 11. It did not appear in the urine. Baseline urinary PGE2 and 6-keto-PGF(1α) excretion were 23.8 ± 5.6 and 18.9 ± 2.7 ng/hr respectively and were reduced by 68{\%} and 47{\%} by day 4 of therapy. TxB2 generation fell by 34{\%} after one dose and by 67{\%} by day 11. There was a significant increase in serum creatinine from 1.88 ± 0.13 mg/dl before treatment to 2.16 ± 0.15 mg/dL (P <.05) after eleven days. There was a significant (P <.001) decrease in effective renal plasma flow, 184.9 ± 16.3 mL/min before therapy vs 164.1 ± 17.0 mL/min on day 11 of therapy. Glomerular filtration rate (GFR) was significantly reduced following 4 days of therapy (P <.05: day 1 vs day 4) but by day 11 had returned to baseline. We concluded than in this population the active sulindac sulfide metabolite accumulates systemically and can significantly inhibit renal prostaglandin metabolism as well as peripheral TxB2 generation and may effect renal function.",
author = "Klassen, {D. K.} and Stout, {R. L.} and Spilman, {P. S.} and A. Whelton",
year = "1989",
language = "English (US)",
volume = "29",
pages = "1037--1042",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency

AU - Klassen, D. K.

AU - Stout, R. L.

AU - Spilman, P. S.

AU - Whelton, A.

PY - 1989

Y1 - 1989

N2 - The purpose of this study was to evaluate the pharmacokinetics of sulindac, a purported 'renal sparing' nonsteroidal anti-inflammatory drug, and its effects on renal function and prostaglandin excretion in patients with reduced glomerular filtration rate. Twelve female patients (glomerular filtration rate 37 ± 4 mL/min) were treated with sulindac 200 mg bid for 11 days. Urinary PGE2, 6-keto-PGF(1α), and serum thromboxane (TxB2) generation were measured by radioimmunoassay (RIA) following extraction on C-18 columns. Glomerular filtration rate and effective renal plasma flow were measured by 99TC-DPTA and 131I-para-aminohippuric acid clearance. In six patients serum and urine levels of sulindac and its metabolites were measured by high-pressure liquid chromatography (HPLC). Sulindac was rapidly absorbed and converted to sulindac sulfide with peak levels 2 hours after a single dose, but steady state levels were not reached prior to drug discontinuation. Sulindac sulfide AUC (0-5 hours μg min/mL) progressively increased from 382 to 3,030 on day 11. It did not appear in the urine. Baseline urinary PGE2 and 6-keto-PGF(1α) excretion were 23.8 ± 5.6 and 18.9 ± 2.7 ng/hr respectively and were reduced by 68% and 47% by day 4 of therapy. TxB2 generation fell by 34% after one dose and by 67% by day 11. There was a significant increase in serum creatinine from 1.88 ± 0.13 mg/dl before treatment to 2.16 ± 0.15 mg/dL (P <.05) after eleven days. There was a significant (P <.001) decrease in effective renal plasma flow, 184.9 ± 16.3 mL/min before therapy vs 164.1 ± 17.0 mL/min on day 11 of therapy. Glomerular filtration rate (GFR) was significantly reduced following 4 days of therapy (P <.05: day 1 vs day 4) but by day 11 had returned to baseline. We concluded than in this population the active sulindac sulfide metabolite accumulates systemically and can significantly inhibit renal prostaglandin metabolism as well as peripheral TxB2 generation and may effect renal function.

AB - The purpose of this study was to evaluate the pharmacokinetics of sulindac, a purported 'renal sparing' nonsteroidal anti-inflammatory drug, and its effects on renal function and prostaglandin excretion in patients with reduced glomerular filtration rate. Twelve female patients (glomerular filtration rate 37 ± 4 mL/min) were treated with sulindac 200 mg bid for 11 days. Urinary PGE2, 6-keto-PGF(1α), and serum thromboxane (TxB2) generation were measured by radioimmunoassay (RIA) following extraction on C-18 columns. Glomerular filtration rate and effective renal plasma flow were measured by 99TC-DPTA and 131I-para-aminohippuric acid clearance. In six patients serum and urine levels of sulindac and its metabolites were measured by high-pressure liquid chromatography (HPLC). Sulindac was rapidly absorbed and converted to sulindac sulfide with peak levels 2 hours after a single dose, but steady state levels were not reached prior to drug discontinuation. Sulindac sulfide AUC (0-5 hours μg min/mL) progressively increased from 382 to 3,030 on day 11. It did not appear in the urine. Baseline urinary PGE2 and 6-keto-PGF(1α) excretion were 23.8 ± 5.6 and 18.9 ± 2.7 ng/hr respectively and were reduced by 68% and 47% by day 4 of therapy. TxB2 generation fell by 34% after one dose and by 67% by day 11. There was a significant increase in serum creatinine from 1.88 ± 0.13 mg/dl before treatment to 2.16 ± 0.15 mg/dL (P <.05) after eleven days. There was a significant (P <.001) decrease in effective renal plasma flow, 184.9 ± 16.3 mL/min before therapy vs 164.1 ± 17.0 mL/min on day 11 of therapy. Glomerular filtration rate (GFR) was significantly reduced following 4 days of therapy (P <.05: day 1 vs day 4) but by day 11 had returned to baseline. We concluded than in this population the active sulindac sulfide metabolite accumulates systemically and can significantly inhibit renal prostaglandin metabolism as well as peripheral TxB2 generation and may effect renal function.

UR - http://www.scopus.com/inward/record.url?scp=0024852335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024852335&partnerID=8YFLogxK

M3 - Article

C2 - 2600190

AN - SCOPUS:0024852335

VL - 29

SP - 1037

EP - 1042

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 11

ER -